How Psilocybin Works in the Brain

Psilocybin doesn’t do much on its own. Your body converts it to psilocin, and psilocin switches on a single serotonin receptor in the cortex called 5-HT2A. Almost everything that follows starts there: the hallucinations, and the shift in mood that can outlast the drug by weeks.

Psilocybin is Schedule I. I don’t prescribe it or offer it. And a compound most people still file under the 1960s is now in late-stage development at the FDA.

How psilocybin works in the brain comes down to five steps, and the evidence is better at some steps than others.

Step	What happens
Psilocybin	Inactive until your body converts it
Psilocin	The active molecule that reaches neurons
5-HT2A receptor	Psilocin switches it on; this drives the experience
Default mode network	Hub regions quiet down and desynchronize
Neuroplasticity	New connections form (proven in animals)

Psilocybin Becomes Psilocin

Swallowed, psilocybin is a prodrug. Enzymes strip off a phosphate group and turn it into psilocin, and psilocin is the molecule that actually reaches your neurons. For where the compound comes from and who first isolated it, see the history of psilocybin.

Psilocin looks enough like serotonin to bind serotonin receptors. Its main target is one subtype: 5-HT2A.

5-HT2A: The One Receptor That Affects Signaling

5-HT2A receptors sit on the apical dendrites of pyramidal neurons, the large output cells of the cortex. Psilocin activates them, and that activation sets off the cascade behind the whole experience.

We know 5-HT2A carries the effect, because blocking it makes the effect disappear. Give someone ketanserin, a drug that blocks 5-HT2A, before psilocybin, and the psychological effects fade in proportion to the dose. Block dopamine instead, and the trip doesn’t weaken. In one study it got stronger. That is the difference between a receptor that is involved and one that is required. For psilocybin, 5-HT2A is required.

This is also why comparing psilocybin to an SSRI misleads people. An SSRI nudges serotonin up across the whole brain over weeks. Psilocin activates one receptor subtype directly and briefly, over a few hours. It is the same neurotransmitter system used in almost the opposite way. It also shows serotonin can shape mood without the slow, whole-brain serotonin boost the old chemical-imbalance theory of depression assumed.

This receptor also answers a question I get from people already on antidepressants. SSRIs work on the same serotonin system, so being on one might blunt psilocybin. In real-world surveys, roughly half the people taking them report weaker-than-expected effects. For some, that lasts months after they stop. The controlled data complicate the folk version, though. In the one randomized test, two weeks of escitalopram before a standard psilocybin dose left the positive effects intact and blunted only the anxiety, bad-trip, and physical side effects. Whether an SSRI forces a higher dose is unproven.

What Happens Across the Brain: The Default Mode Network

The same effect shows up one level up, across whole brain networks. The one that gets the most attention is the default mode network, a set of hub regions, including the medial prefrontal cortex and posterior cingulate, that runs hottest when you are ruminating or mentally time-traveling.

Under psilocybin, those hubs quiet down and stop coordinating the way they normally do. The first strong imaging study showed blood flow dropping in exactly those hubs, and the larger the drop in the medial prefrontal cortex, the more intense the experience felt. A 2024 precision-imaging study went further: psilocybin desynchronized the brain several times more than a stimulant control did, blurred the boundaries between networks, and left one connection, between the anterior hippocampus and the default mode network, weakened for weeks.

But the jump from “networks desynchronize” to “the brain resets” is not something the data support. The team behind that 2024 study called the lingering change a possible correlate of the drug’s effect. They stopped short of calling it a cause, and so should we.

Neuroplasticity: The Part Everyone Overstates

The most exciting and most oversold piece is neuroplasticity, the brain’s capacity to rewire its connections. In mice, a single dose of psilocybin grows new dendritic spines, the tiny contact points between neurons, raising their density by roughly 10 percent within a day and holding for at least a month. That is a striking result. It is also a mouse result.

In humans, nobody has watched psilocybin grow a synapse, because we cannot yet image that in a living human brain. A systematic review of the plasticity evidence found the signal sitting almost entirely in animal work, 16 preclinical studies against 4 clinical ones. The claim that psilocybin “rewires your brain” is half true: it clearly does in rodents, with only indirect hints in people.

Does the Trip Itself Matter?

Is the psychedelic experience what heals people, or just what the drug feels like while the receptor does the real work? Nobody has answered that yet.

In psilocybin trials for depression, the more intense the mystical-type experience during a session, the more the depression lifted afterward, and that experience statistically carried much of the effect. That points to the trip as the active ingredient.

But some compounds skip the trip and still work, at least in animals. Chemists have engineered non-hallucinogenic molecules that produce the same structural changes in mice and antidepressant-like effects, with no subjective experience at all. If that holds in people, the hallucination is optional.

The human evidence is correlational, though, and comes from small, unblinded trials. A strong experience might just track how hard the receptor got hit. The trip-free evidence is all in animals. The question is open, and anyone who calls it settled is ahead of the data.

Sorting real treatment options from hype is most of the work in depression care. If that’s where you are, you can book an evaluation and we’ll go through what actually helps, and what doesn’t.

Why One Dose Might Last

If the drug clears in hours, why would anything change for months? The leading idea is that psilocybin briefly reopens a window of heightened plasticity, similar to the ones open in childhood when the brain learns fast. In mice, several psychedelics reopen a specific social-learning window, and how long it stays open tracks how long each drug’s subjective effects last in people. If the therapeutic work happens while that window is open, the change can outlast the drug.

It’s a clean hypothesis with rodent evidence and a plausible human bridge. The human side is still almost all inference. It gives a reason the therapy pairs the dose with preparation and integration sessions, but it does not prove the model in people yet.

How Psilocybin Works in the Brain, in Three Tiers

The mechanism sorts into three tiers. Proven: psilocybin acts through 5-HT2A, and blocking that receptor switches the effect off in humans. Promising: it desynchronizes brain networks and, at least in animals, drives real structural plasticity, with some changes that persist. Marketing: “brain reset,” “one-and-done cure,” and “better than antidepressants.” The one head-to-head trial against escitalopram did not beat it on the primary measure. For what the trials actually show across psychedelics, see my overview of psychedelics for mental health.

MDMA reaches the same goal by a very different route. See how MDMA-assisted therapy works for the contrast, and why its phase 3 trials stalled at the FDA.

None of this is available at my practice, and under federal law psilocybin stays illegal to use outside a research setting. If you are dealing with depression that has not responded to standard treatment, careful diagnosis and medication management still cover a lot of ground. That is worth a real conversation about treatment-resistant depression and what depression care in North Carolina looks like.

Frequently Asked Questions

Is psilocybin the same as psilocin?

No. Psilocybin is the compound in the mushroom, and it is inactive until your body removes a phosphate group and converts it to psilocin. Psilocin is what acts on the brain’s 5-HT2A receptors.

Does psilocybin actually cause neuroplasticity?

In animals, the evidence is clear. A single dose grows new dendritic spines in mice and the effect lasts weeks. In humans, direct synaptic plasticity has not been measured, because current imaging cannot see it. Treat human “rewiring” claims as an extrapolation from animal data. We can’t confirm it directly in people yet.

Is the psychedelic trip necessary for the antidepressant effect?

It’s unknown and actively debated. Human trials show the intensity of the experience predicts the improvement, while animal work shows non-hallucinogenic analogs can still change the brain. Neither settles it.

How is psilocybin different from ketamine?

They work through different receptors and carry different legal status. Psilocybin acts on serotonin 5-HT2A receptors and is Schedule I. Ketamine acts on glutamate NMDA receptors and is a legal anesthetic. It’s used off-label for depression, and its nasal form, esketamine, is FDA-approved for treatment-resistant depression. Treat them as two separate tools.

Is psilocybin legal or available in North Carolina?

No. Psilocybin is a Schedule I substance under federal law and is not available for clinical use in North Carolina. This article is educational and is not an offer to provide it.

This article is for educational purposes only and is not medical advice. Psilocybin is a Schedule I controlled substance and is not offered, prescribed, or facilitated by Baghel Psychiatry. Nothing here should be read as encouragement to obtain or use it. If you are struggling with depression or thoughts of self-harm, help is available. Call or text 988 to reach the Suicide and Crisis Lifeline.

References

1. Nichols DE. Psychedelics. Pharmacological Reviews. 2016;68(2):264-355. PMID 26841800.
2. Vollenweider FX, et al. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport. 1998;9(17):3897-3902. PMID 9875725.
3. Gukasyan N, et al. Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use. Journal of Psychopharmacology. 2023;37(7):707-716. PMID 37291890.
4. Becker AM, et al. Acute effects of psilocybin after escitalopram or placebo pretreatment in a randomized, double-blind, placebo-controlled, crossover study in healthy subjects. Clinical Pharmacology & Therapeutics. 2022;111(4):886-895. PMID 34743319.
5. Carhart-Harris RL, et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. PNAS. 2012;109(6):2138-2143. PMID 22308440.
6. Siegel JS, et al. Psilocybin desynchronizes the human brain. Nature. 2024;632(8023):131-138. PMID 39020167.
7. Shao LX, et al. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron. 2021;109(16):2535-2544. PMID 34228959.
8. de Vos CMH, et al. Psychedelics and neuroplasticity: a systematic review. Frontiers in Psychiatry. 2021;12:724606. PMID 34566723.
9. Roseman L, Nutt DJ, Carhart-Harris RL. Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Frontiers in Pharmacology. 2018;8:974. PMID 29387009.
10. Griffiths RR, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer. Journal of Psychopharmacology. 2016;30(12):1181-1197. PMID 27909165.
11. Cameron LP, et al. A non-hallucinogenic psychedelic analogue with therapeutic potential. Nature. 2021;589(7842):474-479. PMID 33299186.
12. Nardou R, et al. Psychedelics reopen the social reward learning critical period. Nature. 2023;618(7966):790-798. PMID 37316665.
13. Carhart-Harris R, et al. Trial of psilocybin versus escitalopram for depression. New England Journal of Medicine. 2021;384(15):1402-1411. PMID 33852780.
14. Drug Enforcement Administration. Schedule I hallucinogenic substances (psilocybin, psilocyn), 21 CFR 1308.11(d)(29)-(30). Accessed July 18, 2026. eCFR.